(Riya Saha, Intern Journalist)As the world is grappling with the coronavirus pandemic, which has infected 1.4 crore people, the COVID-19 vaccine is the only respite.
At present, there are more than 150 vaccine candidates to combat the coronavirus in the different stages of the trial across the world, according to the World Health Organisation.
One of the most promising vaccine candidates was the one formulated by the University of Oxford. It has shown positive results in the initial trials, according to various reports. The conclusions of the trials are to be published in The Lancet — a peer-reviewed weekly medical journal. “Tomorrow. Vaccines. Just saying,” Richard Horton, the editor of The Lancet tweeted on Sunday.
Officially known as AZD1222, the vaccine candidate has been developed by the Jenner Institute, a part of the Nuffield Department of Medicine at the University of Oxford. The formulation is backed by AstraZeneca PLC, a British-Swedish pharmaceutical company.
About Post Author
